Literature DB >> 14598073

Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.

A E Di Rosa1, A Epifanio, A Antonini, F Stocchi, G Martino, L Di Blasi, A Tetto, G Basile, D Imbesi, P La Spina, G Di Raimondo, L Morgante.   

Abstract

The aim of this study was to assess whether patients with Parkinson's disease (PD) develop cognitive and psychiatric complications more frequently during prolonged therapy with continuous apomorphine infusion compared with standard oral treatment. Thirty consecutive PD patients with severe motor fluctuations were included in the study. Twelve patients accepted the treatment with subcutaneous continuous apomorphine infusion, while the remaining 18 preferred to continue with oral dopaminergic therapy. The two groups were evaluated with neuropsychological, psychiatric, and motor tests at baseline and after 1 year. The off daily duration and the levodopa dosage were significantly reduced in infused patients. The neuropsychiatric assessment did not change in both groups compared with baseline, except for a significant improvement of mood in the apomorphine group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598073     DOI: 10.1007/s10072-003-0116-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

1.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.

Authors:  Angelo Antonini; Ioannis U Isaias; Giorgia Rodolfi; Andrea Landi; Francesca Natuzzi; Chiara Siri; Gianni Pezzoli
Journal:  J Neurol       Date:  2010-10-23       Impact factor: 4.849

2.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.

Authors:  D De Gaspari; C Siri; A Landi; R Cilia; A Bonetti; F Natuzzi; L Morgante; C B Mariani; E Sganzerla; G Pezzoli; A Antonini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

Review 3.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 4.  Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease.

Authors:  Angelo Antonini; K Ray Chaudhuri; Pablo Martinez-Martin; Per Odin
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

5.  Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.

Authors:  Sophie Drapier; Alexandre Eusebio; Bertrand Degos; Marc Vérin; Franck Durif; Jean Philippe Azulay; François Viallet; Tiphaine Rouaud; Caroline Moreau; Luc Defebvre; Valerie Fraix; Christine Tranchant; Karine Andre; Christine Brefel Courbon; Emmanuel Roze; David Devos
Journal:  J Neurol       Date:  2016-04-08       Impact factor: 4.849

Review 6.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 7.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

8.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 9.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.